Company intelligence / Profile preview

Cirrus Therapeutics

Cambridge, Massachusetts, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Cirrus Therapeutics is a spinout from the University of Bristol developing a gene therapy targeting a key protein in the eye for the treatment of macular degeneration. The company is focused on advancing this novel approach to address unmet needs in ophthalmology.

Therapeutic areas: Ophthalmology
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

1 asset

IRAK-M gene therapy

Preclinical

Partnerships

University of Bristol (academic spinout; no major pharma partnerships listed)

Beyond the preview

Go deeper on Cirrus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cirrus Therapeutics.

Explore the full profile